HIV Vaccine

Elispot Assay May Hasten Development Of African Vaccine

Published in AIDS Weekly, November 5th, 2001

by Michael Greer, senior medical writer - Enzyme-linked immunospot (Elispot) analysis of immune responses to HIV is aiding the development of a vaccine targeting viral strains common in Africa, researchers report.

"The most severe human immunodeficiency virus type 1 (HIV-1) epidemic is occurring in southern Africa," according to Dr. Max Essex and colleagues at the Harvard School of Public Health and Harvard Medical School in Boston, the National Health Laboratory/National Blood Transfusion Center and the Botswana-Harvard Partnership for HIV Research and Education in Gaborone, Botswana, and Los Alamos National Laboratory in Los Alamos, New Mexico. "It is caused by HIV-1...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2001-11-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry